Determination of levetiracetam in human plasma with minimal sample pretreatment

被引:66
作者
Martens-Lobenhoffer, J [1 ]
Bode-Böger, SM [1 ]
机构
[1] Otto Von Guericke Univ, Univ Hosp, Inst Clin Pharmacol, D-39120 Magdeburg, Germany
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2005年 / 819卷 / 01期
关键词
levetiracetam; antiepileptic drugs; porous graphitic carbon; HPLC;
D O I
10.1016/j.jchromb.2005.01.040
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We here present a method for the routine quantification of the novel antiepileptic drug levetiracetam in human serum by HPLC-UV. The procedure is very easy, quick, inexpensive and rugged. The sample preparation consists only in the precipitation of serum proteins by perchloric acid and extraction of unpolar components by cyclohexane. The aqueous phase containing the analyte levetiracetam is injected onto a porous graphitic carbon analytical HPLC-column and separated by gradient elution with diluted phosphoric acid/acetonitrile. Detection is carried out at a wavelength of 205 nm. The calibration function is linear in the range of 1-75 mu g/ml. The detection limit is 0.1 mu g/ml. Using four quality control sample concentrations, the inter-day relative standard deviations (R.S.D.) are lower than 3% and the accuracies are better than 6%. The respective inter-day values are: R.S.D. < 4% and accuracies better than 2%. Frequently co-administered antiepileptic drugs do not interfere with the assay. The method has been successfully applied to patient samples. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:197 / 200
页数:4
相关论文
共 12 条
[1]   Levetiracetam: Relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets [J].
Coupez, R ;
Straetemans, R ;
Sehgal, G ;
Stockis, A ;
Lu, ZH .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (12) :1370-1376
[2]   Levetiracetam: A novel antiepileptic drug [J].
Hovinga, CA .
PHARMACOTHERAPY, 2001, 21 (11) :1375-1388
[3]   Enantioselective analysis of levetiracetam and its enantiomer R-α-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection [J].
Isoherranen, N ;
Roeder, M ;
Soback, S ;
Yagen, B ;
Schurig, V ;
Bialer, M .
JOURNAL OF CHROMATOGRAPHY B, 2000, 745 (02) :325-332
[4]   Pharmacokinetics of levetiracetam and its enantiomer (R)-α-ethyl-2-oxo-pyrrolidine acetamide in dogs [J].
Isoherranen, N ;
Yagen, T ;
Soback, T ;
Roeder, M ;
Schurig, V ;
Bialer, M .
EPILEPSIA, 2001, 42 (07) :825-830
[5]   Microemulsion electrokinetic chromatography applied for separation of levetiracetam from other antiepileptic drugs in polypharmacy [J].
Ivanova, M ;
Piunti, A ;
Marziali, E ;
Komarova, N ;
Raggi, MA ;
Kenndler, E .
ELECTROPHORESIS, 2003, 24 (06) :992-998
[6]   Pharmacokinetic study of levetiracetam in children [J].
Pellock, JM ;
Glauser, TA ;
Bebin, EM ;
Fountain, NB ;
Ritter, FJ ;
Coupez, RM ;
Shields, WD .
EPILEPSIA, 2001, 42 (12) :1574-1579
[7]   The clinical pharmacokinetics of the newer antiepileptic drugs - Focus on topiramate, zonisamide and tiagabine [J].
Perucca, E ;
Bialer, M .
CLINICAL PHARMACOKINETICS, 1996, 31 (01) :29-46
[8]   High-performance liquid chromatographic determination of Levetiracetam in human plasma: comparison of different sample clean-up procedures [J].
Pucci, V ;
Bugamelli, F ;
Mandrioli, R ;
Ferranti, A ;
Kenndler, E ;
Raggi, MA .
BIOMEDICAL CHROMATOGRAPHY, 2004, 18 (01) :37-44
[9]   A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography [J].
Ratnaraj, N ;
Doheny, HC ;
Patsalos, PN .
THERAPEUTIC DRUG MONITORING, 1996, 18 (02) :154-157
[10]   Bioanalytical Method Validation—A Revisit with a Decade of Progress [J].
Vinod P. Shah ;
Kamal K. Midha ;
John W. A. Findlay ;
Howard M. Hill ;
James D. Hulse ;
Iain J. McGilveray ;
Gordon McKay ;
Krys J. Miller ;
Rabindra N. Patnaik ;
Mark L. Powell ;
Alfred Tonelli ;
C. T. Viswanathan ;
Avraham Yacobi .
Pharmaceutical Research, 2000, 17 (12) :1551-1557